Shadi Farabi Maleki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shadi Farabi Maleki has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Ali Jafarizadeh
Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran
5 shared publications - Roohallah Alizadehsani
Institute for Intelligent Systems Research and Innovation (IISRI), Deakin University, Waurn Ponds, VIC, Australia
3 shared publications - Siamak Pedrammehr
Faculty of Design, Tabriz Islamic Art University, Tabriz 5164736931, Iran
3 shared publications - Chee Peng Lim
Swinburne University of Technology
2 shared publications - Houshyar Asadi
Institute for Intelligent Systems Research and Innovation (IISRI), Deakin University, Geelong, VIC 3216, Australia
2 shared publications - Milad Yousefi
Faculty of Mathematics, Statistics, and Computer sciences, University of Tabriz, Tabriz, Iran
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Ophthalmological Medicine
- Vol. 2026 (1)
Refractory Orbital Spindle Cell Carcinoma With Rapid Progression and Intracranial Extension
Spindle cell carcinoma, also known as carcinosarcoma or sarcomatoid carcinoma, is a rare and aggressive variant of squamous cell carcinoma known by biphasic malignant histology with epithelial and mesenchymal differentiation. We report the case of a 72‐year‐old male presenting with progressive unilateral proptosis, upper eyelid swelling, and restricted ocular motility. Imaging showed a well‐defined mass infiltrating multiple orbital structures, histopathologically supporting orbital spindle cell carcinoma after ruling out other mimics. After surgical debulking, followed by chemotherapy and radiotherapy, the tumor showed aggressive invasion with local infiltration, bone destruction, and intracranial extension, which ultimately led to the patient′s death. This case underscores detection and management challenges in the primary orbital spindle cell carcinoma. This tumor′s aggressiveness and resistance to traditional treatment approaches reveal the need for further investigation into its etiology and better management techniques.
- 1 January 2026
- Published by Wiley in Case Reports in Ophthalmological Medicine
- Vol. 2026 (1)
Open AccessRefractory Orbital Spindle Cell Carcinoma With Rapid Progression and Intracranial Extension
Spindle cell carcinoma, also known as carcinosarcoma or sarcomatoid carcinoma, is a rare and aggressive variant of squamous cell carcinoma known by biphasic malignant histology with epithelial and mesenchymal differentiation. We report the case of a 72‐year‐old male presenting with progressive unilateral proptosis, upper eyelid swelling, and restricted ocular motility. Imaging showed a well‐defined mass infiltrating multiple orbital structures, histopathologically supporting orbital spindle cell carcinoma after ruling out other mimics. After surgical debulking, followed by chemotherapy and radiotherapy, the tumor showed aggressive invasion with local infiltration, bone destruction, and intracranial extension, which ultimately led to the patient′s death. This case underscores detection and management challenges in the primary orbital spindle cell carcinoma. This tumor′s aggressiveness and resistance to traditional treatment approaches reveal the need for further investigation into its etiology and better management techniques.
- Top Cited PapersOpen Access
- 29 March 2025
- Published by Springer Nature in Artificial Intelligence Review
- Vol. 58 (6) , 1-55
Current and future roles of artificial intelligence in retinopathy of prematurity
Retinopathy of prematurity (ROP) is a severe condition affecting premature infants, leading to abnormal retinal blood vessel growth, retinal detachment, and potential blindness. While semi-automated systems have been used in the past to diagnose ROP-related plus disease by quantifying retinal vessel features, traditional machine learning (ML) models face challenges like accuracy and overfitting. Recent advancements in deep learning (DL), especially convolutional neural networks (CNNs), have significantly improved ROP detection and classification. The i-ROP deep learning (i-ROP-DL) system also shows promise in detecting plus disease, offering reliable ROP diagnosis potential. This research comprehensively examines the contemporary progress and challenges associated with using retinal imaging and artificial intelligence (AI) to detect ROP, offering valuable insights that can guide further investigation in this domain. Based on 84 original studies in this field (out of 2025 studies that were comprehensively reviewed), we concluded that traditional methods for ROP diagnosis suffer from subjectivity and manual analysis, leading to inconsistent clinical decisions. AI holds great promise for improving ROP management. This review explores AI’s potential in ROP detection, classification, diagnosis, and prognosis.
- 29 March 2025
- Published by Springer Nature in Artificial Intelligence Review
- Vol. 58 (6) , 1-55
Top Cited PapersOpen AccessCurrent and future roles of artificial intelligence in retinopathy of prematurity
Retinopathy of prematurity (ROP) is a severe condition affecting premature infants, leading to abnormal retinal blood vessel growth, retinal detachment, and potential blindness. While semi-automated systems have been used in the past to diagnose ROP-related plus disease by quantifying retinal vessel features, traditional machine learning (ML) models face challenges like accuracy and overfitting. Recent advancements in deep learning (DL), especially convolutional neural networks (CNNs), have significantly improved ROP detection and classification. The i-ROP deep learning (i-ROP-DL) system also shows promise in detecting plus disease, offering reliable ROP diagnosis potential. This research comprehensively examines the contemporary progress and challenges associated with using retinal imaging and artificial intelligence (AI) to detect ROP, offering valuable insights that can guide further investigation in this domain. Based on 84 original studies in this field (out of 2025 studies that were comprehensively reviewed), we concluded that traditional methods for ROP diagnosis suffer from subjectivity and manual analysis, leading to inconsistent clinical decisions. AI holds great promise for improving ROP management. This review explores AI’s potential in ROP detection, classification, diagnosis, and prognosis.
- 30 November 2024
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 33 (1) , 2
Therapeutic role of erythropoietin in methanol induced optic neuropathy: a systematic review
Purpose Despite various therapeutic attempts, an approved treatment for Methanol-induced optic neuropathy (MION), a sight-threatening disorder, is still lacking. Erythropoietin known as an erythropoietic cytokine, possesses various non-hematopoietic properties that make it a candidate for MION treatment. This systematic review aims to assess the potential therapeutic role of erythropoietin in MION. Method We systematically searched English and Persian databases including PubMed, Scopus, Embase, Web of Science, and Scientific Information Database (SID) as of July 2024. Two independent authors screened the articles based on their titles, abstracts, and full texts to finalize the included articles in this study. The selected articles underwent quality assessments via the Joanna Briggs Institute (JBI) checklists. Results Out of 139 studies identified in the databases, 11 were finally included in the analysis. These studies encompassed 212 participants, with 192 receiving erythropoietin treatment. Visual acuity (VA) improved in 184 patients, with improvements ranging from no light perception to full vision recovery, or minor enhancements such as an improvement from 1.75 ± 0.72 to 1.32 ± 0.79 LogMAR. Only 8 patients showed no change or experienced deterioration. Additionally, 21 cases exhibited a reduction in retinal nerve fiber layer thickness, with one showing a reduction towards the normal range. Conclusion This review highlights erythropoietin’s positive impact on VA in patients with MION. However, simultaneous use of erythropoietin and corticosteroids in studies without control groups complicates evaluating erythropoietin’s independent efficacy. Future research should involve large, controlled trials to clarify erythropoietin’s role and establish it as a standard treatment. PROSPERO Registration number CRD42023485772. Graphical Abstract
- 30 November 2024
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 33 (1) , 2
Therapeutic role of erythropoietin in methanol induced optic neuropathy: a systematic review
Purpose Despite various therapeutic attempts, an approved treatment for Methanol-induced optic neuropathy (MION), a sight-threatening disorder, is still lacking. Erythropoietin known as an erythropoietic cytokine, possesses various non-hematopoietic properties that make it a candidate for MION treatment. This systematic review aims to assess the potential therapeutic role of erythropoietin in MION. Method We systematically searched English and Persian databases including PubMed, Scopus, Embase, Web of Science, and Scientific Information Database (SID) as of July 2024. Two independent authors screened the articles based on their titles, abstracts, and full texts to finalize the included articles in this study. The selected articles underwent quality assessments via the Joanna Briggs Institute (JBI) checklists. Results Out of 139 studies identified in the databases, 11 were finally included in the analysis. These studies encompassed 212 participants, with 192 receiving erythropoietin treatment. Visual acuity (VA) improved in 184 patients, with improvements ranging from no light perception to full vision recovery, or minor enhancements such as an improvement from 1.75 ± 0.72 to 1.32 ± 0.79 LogMAR. Only 8 patients showed no change or experienced deterioration. Additionally, 21 cases exhibited a reduction in retinal nerve fiber layer thickness, with one showing a reduction towards the normal range. Conclusion This review highlights erythropoietin’s positive impact on VA in patients with MION. However, simultaneous use of erythropoietin and corticosteroids in studies without control groups complicates evaluating erythropoietin’s independent efficacy. Future research should involve large, controlled trials to clarify erythropoietin’s role and establish it as a standard treatment. PROSPERO Registration number CRD42023485772. Graphical Abstract
- Open Access
- 2 July 2024
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 46 (4) , 355-370
Effects of Donepezil on Clinical Symptoms, Language, and Executive Skills in Individuals with Autism Spectrum Disorder: A Systematic Review
Background. This study assessed the potential efficacy of donepezil in treating autism spectrum disorder (ASD), a neurodevelopmental condition characterized by social communication difficulties and repetitive behaviors. Donepezil, primarily used to treat Alzheimer’s disease as an acetylcholinesterase inhibitor, has gained attention as a potential treatment for ASD symptoms. Methods. Following PRISMA guidelines, a systematic review was conducted to investigate the effects of donepezil on individuals with ASD. Outcome measures assessed various aspects of ASD, including language skills, executive function, behavior, and core symptoms. Nine studies were identified, including four randomized controlled trials (RCTs), three retrospective studies, one open-label trial, and one case report. Results. One RCT reported significant improvements in expressive and receptive language skills, especially in younger children. Another study combining donepezil with choline supplementation showed enhanced receptive language skills, particularly in younger participants. An open-label trial indicated improved rapid eye movement sleep patterns in autistic children treated with donepezil. Several retrospective studies reported improvements in behavioral symptoms, such as aggression and hyperactivity. However, other RCTs did not find statistically significant improvements in executive functioning. Conclusion. In general, donepezil use in ASD demonstrates promise in specific areas, notably language development and behavioral symptom management. However, the results are contradictory, requiring further research to clarify its role, optimal dosing, long-term effects, and potential side effects in individuals with ASD. Practical Implications. Donepezil can be used to improve the clinical global impression and language skills of people with ASD.
- 2 July 2024
- Published by Maad Rayan Publishing Company in Medical Journal of Tabriz University of Medical Sciences
- Vol. 46 (4) , 355-370
Open AccessEffects of Donepezil on Clinical Symptoms, Language, and Executive Skills in Individuals with Autism Spectrum Disorder: A Systematic Review
Background. This study assessed the potential efficacy of donepezil in treating autism spectrum disorder (ASD), a neurodevelopmental condition characterized by social communication difficulties and repetitive behaviors. Donepezil, primarily used to treat Alzheimer’s disease as an acetylcholinesterase inhibitor, has gained attention as a potential treatment for ASD symptoms. Methods. Following PRISMA guidelines, a systematic review was conducted to investigate the effects of donepezil on individuals with ASD. Outcome measures assessed various aspects of ASD, including language skills, executive function, behavior, and core symptoms. Nine studies were identified, including four randomized controlled trials (RCTs), three retrospective studies, one open-label trial, and one case report. Results. One RCT reported significant improvements in expressive and receptive language skills, especially in younger children. Another study combining donepezil with choline supplementation showed enhanced receptive language skills, particularly in younger participants. An open-label trial indicated improved rapid eye movement sleep patterns in autistic children treated with donepezil. Several retrospective studies reported improvements in behavioral symptoms, such as aggression and hyperactivity. However, other RCTs did not find statistically significant improvements in executive functioning. Conclusion. In general, donepezil use in ASD demonstrates promise in specific areas, notably language development and behavioral symptom management. However, the results are contradictory, requiring further research to clarify its role, optimal dosing, long-term effects, and potential side effects in individuals with ASD. Practical Implications. Donepezil can be used to improve the clinical global impression and language skills of people with ASD.
- Open Access
Advancements in Radiomics and Artificial Intelligence for Thyroid Cancer Diagnosis
Thyroid cancer is an increasing global health concern that requires advanced diagnostic methods. The application of AI and radiomics to thyroid cancer diagnosis is examined in this review. A review of multiple databases was conducted in compliance with PRISMA guidelines until October 2023. A combination of keywords led to the discovery of an English academic publication on thyroid cancer and related subjects. 267 papers were returned from the original search after 109 duplicates were removed. Relevant studies were selected according to predetermined criteria after 124 articles were eliminated based on an examination of their abstract and title. After the comprehensive analysis, an additional six studies were excluded. Among the 28 included studies, radiomics analysis, which incorporates ultrasound (US) images, demonstrated its effectiveness in diagnosing thyroid cancer. Various results were noted, some of the studies presenting new strategies that outperformed the status quo. The literature has emphasized various challenges faced by AI models, including interpretability issues, dataset constraints, and operator dependence. The synthesized findings of the 28 included studies mentioned the need for standardization efforts and prospective multicenter studies to address these concerns. Furthermore, approaches to overcome these obstacles were identified, such as advances in explainable AI technology and personalized medicine techniques. The review focuses on how AI and radiomics could transform the diagnosis and treatment of thyroid cancer. Despite challenges, future research on multidisciplinary cooperation, clinical applicability validation, and algorithm improvement holds the potential to improve patient outcomes and diagnostic precision in the treatment of thyroid cancer.
Open AccessAdvancements in Radiomics and Artificial Intelligence for Thyroid Cancer Diagnosis
Thyroid cancer is an increasing global health concern that requires advanced diagnostic methods. The application of AI and radiomics to thyroid cancer diagnosis is examined in this review. A review of multiple databases was conducted in compliance with PRISMA guidelines until October 2023. A combination of keywords led to the discovery of an English academic publication on thyroid cancer and related subjects. 267 papers were returned from the original search after 109 duplicates were removed. Relevant studies were selected according to predetermined criteria after 124 articles were eliminated based on an examination of their abstract and title. After the comprehensive analysis, an additional six studies were excluded. Among the 28 included studies, radiomics analysis, which incorporates ultrasound (US) images, demonstrated its effectiveness in diagnosing thyroid cancer. Various results were noted, some of the studies presenting new strategies that outperformed the status quo. The literature has emphasized various challenges faced by AI models, including interpretability issues, dataset constraints, and operator dependence. The synthesized findings of the 28 included studies mentioned the need for standardization efforts and prospective multicenter studies to address these concerns. Furthermore, approaches to overcome these obstacles were identified, such as advances in explainable AI technology and personalized medicine techniques. The review focuses on how AI and radiomics could transform the diagnosis and treatment of thyroid cancer. Despite challenges, future research on multidisciplinary cooperation, clinical applicability validation, and algorithm improvement holds the potential to improve patient outcomes and diagnostic precision in the treatment of thyroid cancer.
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 21 (3) , 155-165
Artificial Intelligence in Eye Movements Analysis for Alzheimer’s Disease Early Diagnosis
: As the world's population ages, Alzheimer's disease is currently the seventh most common cause of death globally; the burden is anticipated to increase, especially among middle-class and elderly persons. Artificial intelligence-based algorithms that work well in hospital environments can be used to identify Alzheimer's disease. A number of databases were searched for English-language articles published up until March 1, 2024, that examined the relationships between artificial intelligence techniques, eye movements, and Alzheimer's disease. A novel non-invasive method called eye movement analysis may be able to reflect cognitive processes and identify anomalies in Alzheimer's disease. Artificial intelligence, particularly deep learning, and machine learning, is required to enhance Alzheimer's disease detection using eye movement data. One sort of deep learning technique that shows promise is convolutional neural networks, which need further data for precise classification. Nonetheless, machine learning models showed a high degree of accuracy in this context. Artificial intelligence-driven eye movement analysis holds promise for enhancing clinical evaluations, enabling tailored treatment, and fostering the development of early and precise Alzheimer's disease diagnosis. A combination of artificial intelligence-based systems and eye movement analysis can provide a window for early and non-invasive diagnosis of Alzheimer's disease. Despite ongoing difficulties with early Alzheimer's disease detection, this presents a novel strategy that may have consequences for clinical evaluations and customized medication to improve early and accurate diagnosis.
- 1 March 2024
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 21 (3) , 155-165
Artificial Intelligence in Eye Movements Analysis for Alzheimer’s Disease Early Diagnosis
: As the world's population ages, Alzheimer's disease is currently the seventh most common cause of death globally; the burden is anticipated to increase, especially among middle-class and elderly persons. Artificial intelligence-based algorithms that work well in hospital environments can be used to identify Alzheimer's disease. A number of databases were searched for English-language articles published up until March 1, 2024, that examined the relationships between artificial intelligence techniques, eye movements, and Alzheimer's disease. A novel non-invasive method called eye movement analysis may be able to reflect cognitive processes and identify anomalies in Alzheimer's disease. Artificial intelligence, particularly deep learning, and machine learning, is required to enhance Alzheimer's disease detection using eye movement data. One sort of deep learning technique that shows promise is convolutional neural networks, which need further data for precise classification. Nonetheless, machine learning models showed a high degree of accuracy in this context. Artificial intelligence-driven eye movement analysis holds promise for enhancing clinical evaluations, enabling tailored treatment, and fostering the development of early and precise Alzheimer's disease diagnosis. A combination of artificial intelligence-based systems and eye movement analysis can provide a window for early and non-invasive diagnosis of Alzheimer's disease. Despite ongoing difficulties with early Alzheimer's disease detection, this presents a novel strategy that may have consequences for clinical evaluations and customized medication to improve early and accurate diagnosis.
- 13 December 2023
- Published by Taylor & Francis in Seminars in Ophthalmology
- Vol. 39 (4) , 271-288
Artificial Intelligence for Multiple Sclerosis Management Using Retinal Images: Pearl, Peaks, and Pitfalls
Multiple sclerosis (MS) is a complex autoimmune disease characterized by inflammatory processes, demyelination, neurodegeneration, and axonal damage within the central nervous system (CNS). Retinal imaging, particularly Optical coherence tomography (OCT), has emerged as a crucial tool for investigating MS-related retinal injury. The integration of artificial intelligence(AI) has shown promise in enhancing OCT analysis for MS. Researchers are actively utilizing AI algorithms to accurately detect and classify MS-related abnormalities, leading to improved efficiency in diagnosis, monitoring, and personalized treatment planning. The prognostic value of AI in predicting MS disease progression has garnered substantial attention. Machine learning (ML) and deep learning (DL) algorithms can analyze longitudinal OCT data to forecast the course of the disease, providing critical information for personalized treatment planning and improved patient outcomes. Early detection of high-risk patients allows for targeted interventions to mitigate disability progression effectively. As such, AI-driven approaches yielded remarkable abilities in classifying distinct MS subtypes based on retinal features, aiding in disease characterization and guiding tailored therapeutic strategies. Additionally, these algorithms have enhanced the accuracy and efficiency of OCT image segmentation, streamlined diagnostic processes, and reduced human error. This study reviews the current research studies on the integration of AI,including ML and DL algorithms, with OCT in the context of MS. It examines the advancements, challenges, potential prospects, and ethical concerns of AI-powered techniques in enhancing MS diagnosis, monitoring disease progression, revolutionizing patient care, the development of patient screening tools, and supported clinical decision-making based on OCT images.
- 13 December 2023
- Published by Taylor & Francis in Seminars in Ophthalmology
- Vol. 39 (4) , 271-288
Artificial Intelligence for Multiple Sclerosis Management Using Retinal Images: Pearl, Peaks, and Pitfalls
Multiple sclerosis (MS) is a complex autoimmune disease characterized by inflammatory processes, demyelination, neurodegeneration, and axonal damage within the central nervous system (CNS). Retinal imaging, particularly Optical coherence tomography (OCT), has emerged as a crucial tool for investigating MS-related retinal injury. The integration of artificial intelligence(AI) has shown promise in enhancing OCT analysis for MS. Researchers are actively utilizing AI algorithms to accurately detect and classify MS-related abnormalities, leading to improved efficiency in diagnosis, monitoring, and personalized treatment planning. The prognostic value of AI in predicting MS disease progression has garnered substantial attention. Machine learning (ML) and deep learning (DL) algorithms can analyze longitudinal OCT data to forecast the course of the disease, providing critical information for personalized treatment planning and improved patient outcomes. Early detection of high-risk patients allows for targeted interventions to mitigate disability progression effectively. As such, AI-driven approaches yielded remarkable abilities in classifying distinct MS subtypes based on retinal features, aiding in disease characterization and guiding tailored therapeutic strategies. Additionally, these algorithms have enhanced the accuracy and efficiency of OCT image segmentation, streamlined diagnostic processes, and reduced human error. This study reviews the current research studies on the integration of AI,including ML and DL algorithms, with OCT in the context of MS. It examines the advancements, challenges, potential prospects, and ethical concerns of AI-powered techniques in enhancing MS diagnosis, monitoring disease progression, revolutionizing patient care, the development of patient screening tools, and supported clinical decision-making based on OCT images.